Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Project PrEPare (Truvada in YMSM)
NCT01769456Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2013
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Number of Participants With Serum Creatinine Event of Grade 1 or Higher at 48 weeks and Lumbar Spine Bone Mineral Density: Percent Change From Baseline to Week 48. Started Mar 2013; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01769456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769456.